9 results about "Ischemic Heart Diseases" patented technology

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

This application relates to the field of gene transduction technology, specifically disclosing a method and application for modifying mesenchymal stem cells (MSCs) targeting myocardial injury. The method includes: S1, obtaining umbilical cord-derived MSCs; S2, performing surface biomimetic modification on the MSCs; S3, gene editing on the MSCs; and S4, co-incubating the engineered MSCs with enzyme-responsive liposomes loaded with nitric oxide donors. The liposomes are embedded in a gelatin coating on the cell membrane surface through hydrophobic interactions, forming a targeted therapeutic system. This method for modifying MSCs targeting myocardial injury can be used for regenerative therapy and repair of myocardial injury diseases such as myocardial infarction and ischemic heart disease. It comprehensively improves the survival and stress tolerance of cells after implantation and enhances the targeting precision to the damaged site, thereby achieving the advantages of efficient, precise, and highly adaptable myocardial repair.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

Reganoxonin is used in the preparation of a drug for the detection of ischemic heart disease by echocardiography. Echocardiography is selected from one or more of stress echocardiography, myocardial angiography, transthoracic Doppler echocardiography, and two-dimensional speckle tracking echocardiography. Ischemic heart disease is selected from one or more of non-obstructive or obstructive ischemic heart disease. The diagnosis of the patient's disease by administering the drug has good accuracy, sensitivity, specificity, and safety.

This invention belongs to the field of biomedical technology, specifically relating to a composition for treating ischemic heart disease and its application. This invention combines two or more of ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re, and notoginsenoside R1, which can significantly downregulate the levels of myocardial enzymes, aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) in myocardial coronary effusion, with an inhibitory effect significantly higher than that of a single saponin component and the positive control drug verapamil. Simultaneously, the composition exhibits better recovery capabilities for coronary flow (CF), left ventricular developmental pressure (LVDP), maximum rate of decrease in left ventricular pressure (-dp / dtmax), and heart rate (HR) in myocardial coronary effusion. Therefore, the composition can alleviate and treat myocardial ischemia-reperfusion injury through multiple targets and mechanisms, fundamentally inhibiting the development of ischemic heart disease.

The application discloses a kind of adipose tissue-derived mitochondrial-derived vesicles and its preparation method and application, belong to the field of biological medicine.The preparation method includes obtaining mouse adipose tissue, including at least one of interscapular brown adipose tissue, epididymal white adipose tissue, beige adipose tissue, in vitro cultured adipocyte;Mouse adipose tissue homogenate is removed by differential centrifugation Unbroken cell, nucleus, mitochondrial and organelle precipitate, the supernatant obtained is treated by trypsin and then ultracentrifuged, the precipitate is collected, washed, to obtain mitochondrial-derived vesicles, which are membrane-coated vesicles, with a particle size of 100-200 nm, enriched in mitochondrial membrane proteins and oxidative phosphorylation-related proteins, and proved by ischemic heart disease model that it can improve heart function, reduce the degree of ventricular remodeling in mice with ischemic heart disease and reduce the fibrosis area, for the preparation of drugs for preventing or treating ischemic heart disease, and has important clinical application value.

Based on combination therapy, we propose a cell therapy that can significantly enhance the therapeutic effect of treatment for cerebrovascular disease, ischemic heart disease, or traumatic cerebrospinal nerve injury in subjects compared to conventional methods. [Solution] A cell preparation containing microglia and / or monocytes, which have the ability to promote angiogenesis and axon extension, is administered to the subject. By repeatedly implementing a bidirectional biofeedback loop between the nervous system and the musculoskeletal system, the effect of improving the motor function of the subject's brain, nervous system, and muscular system is enhanced.

Provided is a coronary blood flow measurement device capable of acquiring significant information for determination of ischemic heart disease caused by stenosis or the like in a coronary blood vessel on the basis of measurement of a blood flow (coronary blood flow) in a blood vessel (coronary blood vessel) of a heart. This coronary blood flow measurement device (10) includes: a CFR acquisition means (12) for acquiring a calculated value of coronary blood flow reserve (CFR); and a cCFR calculation means (14) for obtaining a blood pressure correction CFR (cCFR) by converting the calculated value of the coronary blood flow reserve (CFR) acquired by the CFR acquisition means into a value under a condition of an arbitrary specific value (ΔPs) of an arteriovenous pressure difference (ΔP(a-v)) by using a linear relationship between a maximum hyperemia coronary blood flow (Q(hyp.)) and the arteriovenous pressure difference (ΔP(a-v)).

The application relates to the field of biological medicine, and provides application of OpiCa1 mutant peptide DE-4A in antagonizing heart failure after myocardial infarction. Experiments prove that the polypeptide DE-4A can remodel myocardial calcium homeostasis by restoring RyR2 protein stability and blocking excessive activation of the CaMKII signal pathway. This mechanism effectively reduces myocardial injury and fibrosis, significantly improves ventricular remodeling and heart dysfunction after myocardial infarction, and provides new experimental evidence for the treatment of ischemic cardiomyopathy. DE-4A has the effects of improving myocardial contractile function, regulating Ca 2+ homeostasis, which may be a key link in the pharmacodynamic mechanism, and provides new experimental evidence for the treatment of ischemic heart disease.